Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard first-line therapy for newly diagnosed glioblastoma with or without add-on Trivax
2009-015979-27Phase 2Completed
- Sponsor
- Activartis Biotech GmbH
- Start
- Dec 2009
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Trivax in glioblastoma (GBM) (2 arms), sponsored by Activartis Biotech GmbH. Primary endpoint: Progression-free survival at 12 months. Started Dec 2009; status: completed.
02
Drugs
Trivax
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-015979-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015979-27.